Abstract:Objectives The tuning effects of JAK/TYK2 inhibitors on the imbalance between T follicular helper (Tfh) and T regulatory (Treg) cells, related to systemic lupus erythematosus (SLE) pathogenesis, were investigated using human peripheral blood samples. Methods Peripheral blood mononuclear cells from untreated patients with SLE and healthy controls were analysed. Tfh1 cells were identified in nephritis tissue, and the effect of Tfh1 cells on B-cell differentiation was examined by coculturing naïve B cells with Tfh1 cells. Results Tfh1 cell numbers were increased in the peripheral blood of patients, and activated Treg cell counts were decreased relative to Tfh1 cell counts. This imbalance in the Tfh to Treg ratio was remarkably pronounced in cases of lupus nephritis, especially in types III and IV active nephritis. Immunohistochemistry revealed Tfh1 cell infiltration in lupus nephritis tissues. Co-culture of Tfh1 cells (isolated from healthy individuals) with naïve B cells elicited greater induction of T-bet + B cells than controls. In JAK/TYK2-dependent STAT phosphorylation assays using memory CD4 + T cells, IL-12-induced STAT1/4 phosphorylation and Tfh1 cell differentiation were inhibited by both JAK and TYK2 inhibitors. However, phosphorylation of STAT5 by IL-2 and induction of Treg cell differentiation by IL-2+TGFβ were inhibited by JAK inhibitors but not by TYK2 inhibitors, suggesting that TYK2 does not mediate the IL-2 signalling pathway. Conclusions Tfh1 cells can induce T-bet + B cell production and may contribute to SLE pathogenesis-associated processes. TYK2 inhibitor may fine-tune the immune imbalance by suppressing Tfh1 differentiation and maintaining Treg cell differentiation, thereby preserving IL-2 signalling, unlike other JAK inhibitors.

What problem does this paper attempt to address?

The paper attempts to address the potential application of TYK2 inhibitors in the treatment of systemic lupus erythematosus (SLE), particularly by improving disease status through the regulation of the imbalance between T cell subsets (specifically Tfh1 and Treg cells). ### Specific research questions include: 1. **Imbalance between Tfh1 cells and Treg cells**: Researchers found that in untreated SLE patients, the number of Tfh1 cells increased while the number of activated Treg cells decreased, leading to an imbalance in the Tfh1/Treg ratio. This imbalance is particularly evident in patients with active lupus nephritis (LN). 2. **Function of Tfh1 cells**: Whether Tfh1 cells can induce the differentiation of T-bet+ B cells and potentially participate in the pathological process of SLE, especially lupus nephritis. 3. **Mechanism of action of TYK2 inhibitors**: Whether TYK2 inhibitors can adjust immune imbalance by inhibiting the differentiation of Tfh1 cells while maintaining the differentiation of Treg cells, unlike other JAK inhibitors that inhibit the IL-2 signaling pathway. ### Research background: - **Pathological mechanism of SLE**: SLE is an autoimmune disease involving multiple organ damage and the production of various autoantibodies. Its pathogenesis is complex, including both innate and acquired immune abnormalities. - **Tfh1 cells and Treg cells**: The increase of Tfh1 cells and the decrease of Treg cells in SLE patients may lead to immune imbalance. - **JAK/TYK2 inhibitors**: JAK/TYK2 inhibitors have shown potential in the treatment of SLE, but their specific mechanisms of action and effects on different T cell subsets are not fully understood. ### Research methods: - **Sample source**: Mononuclear cells were isolated from the peripheral blood of 82 newly diagnosed or relapsed untreated SLE patients and 66 healthy controls. - **Cell phenotype analysis**: The number and ratio of Tfh1 cells and Treg cells were detected by flow cytometry. - **Co-culture experiments**: Tfh1 cells isolated from the peripheral blood of healthy controls were co-cultured with naive B cells to observe the effect of Tfh1 cells on B cell differentiation. - **Signaling pathway analysis**: The effect of JAK/TYK2 inhibitors on the IL-12 and IL-2 signaling pathways was evaluated by STAT phosphorylation experiments. ### Main findings: - **Imbalance between Tfh1 cells and Treg cells**: The number of Tfh1 cells significantly increased in SLE patients, while the number of activated Treg cells decreased, leading to an imbalance in the Tfh1/Treg ratio. - **Function of Tfh1 cells**: Tfh1 cells can induce the differentiation of naive B cells into T-bet+ B cells, which may be involved in the pathological process of lupus nephritis. - **Effect of TYK2 inhibitors**: TYK2 inhibitors can inhibit the differentiation of Tfh1 cells while maintaining the differentiation of Treg cells, unlike other JAK inhibitors that inhibit the IL-2 signaling pathway. ### Conclusion: - **Potential application of TYK2 inhibitors**: TYK2 inhibitors may improve the immune imbalance in SLE patients by adjusting the balance between Tfh1 and Treg cells, particularly in patients with increased Tfh1 cells and decreased Treg cells, showing potential therapeutic value. This study provides new scientific evidence for the precise treatment of SLE, especially for patients with increased Tfh1 cells and decreased Treg cells.

Modifying T cell phenotypes using TYK2 inhibitor and its implications for the treatment of systemic lupus erythematosus

Dysregulated T Cell Activation and Aberrant Cytokine Expression Profile in Systemic Lupus Erythematosus.

Aberrant T Cell Subsets and Cytokines Expression Profile in Systemic Lupus Erythematosus.

OP0043 the Number of Circulating Regulatory T Cells is Reduced and Low-Dose Il-2 Selectively Stimulates Its Proliferation in Patients with Systemic Lupus Erythematosus

TYK2 inhibition enhances Treg differentiation and function while preventing Th1 and Th17 differnetiation

Pathological relevance and treatment perspective of JAK targeting in systemic lupus erythematosus

JAK inhibitor has the amelioration effect in lupus-prone mice: the involvement of IFN signature gene downregulation

Tofacitinib Ameliorates Lupus Through Suppression of T Cell Activation Mediated by TGF-Beta Type I Receptor

Sustained Low‐dose Interleukin‐2 Therapy Alleviates Pathogenic Humoral Immunity Via Elevating the Tfr/Tfh Ratio in Lupus

TYK2: an emerging therapeutic target in rheumatic disease

Pathogenic and Therapeutic Relevance of JAK/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent

Concomitant use of interleukin-2 and tacrolimus suppresses follicular helper T cell proportion and exerts therapeutic effect against lupus nephritis in systemic lupus erythematosus-like chronic graft versus host disease

Targeting TYK2 for Fighting Diseases: Recent Advance of TYK2 Inhibitors

Tyrosine Kinase 2 Inhibitors: Synthesis and Applications in the Treatment of Autoimmune Diseases

Cytotoxic Tph subset with low B-cell helper functions and its involvement in systemic lupus erythematosus

Mechanisms of Tumor Necrosis Factor-Alpha Inhibitor-Induced Systemic Lupus Erythematosus

T Follicular Helper Cells and Regulatory B Cells Dynamics in Systemic Lupus Erythematosus.

Th1, Th2, and Th17 cytokines in systemic lupus erythematosus

Cutting Edge: Low-dose Recombinant IL-2 Treatment Prevents Autoantibody Responses in Systemic Lupus Erythematosus via Regulatory T Cell-independent Depletion of T Follicular Helper Cells

TLR7 Protein Expression in Mild and Severe Lupus-Prone Models Is Regulated in a Leukocyte, Genetic, and IRAK4 Dependent Manner

Modulation of PKM2 inhibits follicular helper T cell differentiation and ameliorates inflammation in lupus-prone mice